Customized Apple iPad Air Enhances Doctor-Patient Interactions in Clinical Trials
BBK Worldwide (BBK), the global leader in patient recruitment, announced today Study eBinder 3.0, the latest generation of its novel clinical trial management tool. The release of this product builds upon the success of earlier models by offering a dramatically more customized and tailored tablet experience for on-the-go study teams. Utilizing BBK's patented TrialCentralNet (TCN®) patient recruitment portal, Study eBinder 3.0 ensures compliance by providing more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff.
"The conversation is no longer about tech adoption as today's tablet culture continues to widen," said Matt Kibby, principal, technology and innovation, BBK Worldwide. "Thirty-five percent of Americans own tablets and that number is growing. BBK was the first to translate tablets into the clinical R&D industry, ensuring clinical trial management stays top of mind."
BBK's Study eBinder 3.0 is fully customizable for both the sponsor's brand and content. With an ultimate goal of enrolling studies sooner than ever before, the metrics-driven resource is effortless to implement.
"Sites are quick to adopt this new technology," said Lucas Garmon, media strategist, BBK Worldwide. "Universal implementation of online resources across devices guarantees individuals have the most critical information at all times. From coordinating study appointments to reviewing the informed consent with patients, we have seen sites begin to rely on their ability to manage studies remotely."
Study eBinder 3.0 is also available in a restricted sponsor view, as well as a patient view, which includes condition-specific information, tips for study participation, and customized retention tools. To learn more, visit shop.BBKWorldwide.com/products/ebinder-study-ipads.
About BBK Worldwide (bbkworldwide.com)
Founded in 1983, BBK Worldwide is the recognized global leader in patient recruitment. The company is renowned for accelerating time to market for new and improved medicines and treatments. Through its partner companies, TCN Technologies and Agency320, BBK offers the industry the most sophisticated technology, creative, and media services. BBK is certified as a Safe Harbor company.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.